TABLE 1.
IBD (n = 937) | UC (n = 446) | CD (n = 491) | P value | |
---|---|---|---|---|
Age, years, median (range) | 44 (10‐86) | 47 (10‐86) | 43 (12‐84) | <0.001 |
Age ≥60 years, n (%) | 185 (19.7) | 106 (23.7) | 75 (15.2) | 0.003 |
Males, n (%) | 513 (54.7) | 252 (56.5) | 261 (53.1) | 0.43 |
Current smokers, n (%) | 148 (15.8) | 59 (13.2) | 89 (18.1) | 0.05 |
Disease duration, years, median (range) | 11 (0‐71) | 11 (0‐61) | 11 (0‐71) | 1.00 |
Disease activity, n (%) | ||||
Remission | 559 (59.6) | 254 (56.9) | 305 (62.1) | 0.002 |
Mild | 211 (22.5) | 99 (22.1) | 112 (22.8) | 0.002 |
Moderate | 124 (13.2) | 63 (14.1) | 61 (12.4) | 0.89 |
Severe | 41 (4.3) | 20 (4.4) | 21 (4.2) | 1.00 |
Therapy, n (%) a | ||||
None | 56 (6.0) | 20 (4.4) | 36 (7.3) | 0.11 |
Salicylates | 492 (52.5) | 333 (74.6) | 159 (32.3) | <0.001 |
Corticosteroids | 122 (13.0) | 70 (15.6) | 52 (10.5) | 0.04 |
Immunomodulators | 101 (11.2) | 47 (10.5) | 54 (10.9) | 0.75 |
TNF antagonists | 346 (36.9) | 114 (25.5) | 232 (47.2) | <0.001 |
TNF antagonists + immunomodulators | 22 (2.3) | 9 (2.0) | 13 (2.6) | 0.61 |
Vedolizumab | 115 (12.3) | 71 (15.9) | 44 (8.9) | <0.001 |
Ustekinumab | 51 (5.4) | 4 (0.9) | 47 (9.5) | <0.001 |
Other | 13 (1.4) | 8 (1.7) | 5 (1.0) | 0.50 |
Comorbidities, n (%) | 376 (40.1) | 188 (42.1) | 188 (38.2) | 0.32 |
IMID | 116 (12.4) | 47 (10.5) | 69 (14.1) | 0.11 |
Arterial hypertension b | 89 (9.5) | 55 (12.3) | 34 (6.9) | 0.01 |
Obesity c | 21 (2.2) | 12 (2.6) | 9 (1.8) | 0.55 |
Charlson's comorbidity index, n (%) | ||||
0 | 538 (57.4) | 234 (52.5) | 311 (63.3) | <0.001 |
1 | 178 (20.7) | 96 (21.5) | 84 (17.1) | 0.34 |
2 | 102 (21.9) | 57 (12.8) | 68 (13.8) | 0.08 |
3 | 59 (6.2) | 32 (7.2) | 27 (5.4) | 0.06 |
4 | 18 (1.9) | 9 (2.0) | 9 (1.8) | 0.05 |
5 | 15 (1.6) | 10 (2.2) | 5 (1.0) | 0.25 |
6 | 9 (0.9) | 6 (1.3) | 3 (0.6) | 0.21 |
7 | 1 (0.1) | 1 (0.2) | 0 (0) | 1.00 |
8 | 1 (0.1) | 1 (0.2) | 0 (0) | 1.00 |
Abbreviations: CD, Crohn's disease; IMID, immune‐mediated inflammatory disease; UC, ulcerative colitis.
The data reflect the fact that some patients were taking more than one therapy simultaneously.
Defined as >140/90 mm Hg.
Body mass index >30 kg/m2.